<DOC>
	<DOCNO>NCT00154791</DOCNO>
	<brief_summary>We plan conduct phase I/II clinical trial use biweekly gemcitabine , oxaliplatin , 48-hour infusion high dose 5-FU/leucovorin treat patient advance pancreatic adenocarcinoma . In phase I part , maximum tolerable dose oxaliplatin combination biweekly gemcitabine 800 mg/m2 48-hour infusion 5-FU 3000 mg/m2 leucovorin 300 mg/m2 determine . In phase II part , efficacy safety biweekly chemotherapy GOFL evaluate .</brief_summary>
	<brief_title>Phase I/II Trial GOFL Advanced Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>For dose GOFL chemotherapy , intravenous infusion gemcitabine fix rate 10 mg/m2/min immediately follow 2-hour intravenous infusion oxaliplatin 48-hour intravenous infusion 5-FU leucovorin.The start dose oxaliplatin phase I part 65 mg/m2 , dose increment 10 mg/m2 . Since recommend dose biweekly single dose oxaliplatin 85 mg/m2 , dose escalation oxaliplatin beyond 85 mg/m2.Patients enter cohort three.If one three patient develop DLT , three additional patient accrue dose level.9.1.3 The six patient treat MTD dose level include phase II part study measurable lesion ( ) prior chemotherapy.For phase II part , If three responder observe initial 21 evaluable patient , trial proceed second stage . Additional 24 patient accrued second stage phase II part .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>5.1.1 Patients must metastatic unresectable adenocarcinoma pancreas . The diagnosis pancreatic adenocarcinoma must confirm histopathology cytology . 5.1.2 For phase I part trial , patient disease measurable evaluable xray , CAT scan , physical examination eligible . For phase II part trial , patient disease measurable xray , CAT scan , physical examination eligible . 5.1.3 Patients must history prior chemotherapy . 5.1.4 Patients prior radiotherapy eligible irradiated area source measurable evaluable disease . 5.1.5 Patients ’ baseline ECOG performance status must £ 2 . 5.1.6 Patients ’ life expectancy must 12 week great . 5.1.7 Patients ’ age must ³ 20 £ 75 . 5.1.8 Patients must adequate bone marrow function , define WBC count ³ 3,500/ul , neutrophil count ³ 1,500/ul , platelet count ³ 100,000/ul . 5.1.9 Patients must adequate liver function adequate renal function , define follow : serum alanine ( ALT ) £ 5 time upper normal limit , serum total bilirubin level £ 2.0 mg/dL , serum creatinine £ 1.5 mg/dL . 5.1.10 Patients biliary obstruction undergone adequate drainage procedure enrollment eligible . 5.1.11 Patients must agree indwell venous catheter implant . 5.1.12 Women men reproductive potential may participate unless agree use effective contraceptive method . 5.1.13 All patient must inform investigational nature study must sign give write informed consent . 5.2.1 Patients central nervous system metastasis 5.2.2 Patients active infection 5.2.3 Pregnant breastnursing woman 5.2.4 Patients active cardiac disease history ischemic heart disease 5.2.5 Patients peripheral neuropathy &gt; Grade I etiology 5.2.6 Patients serious concomitant systemic disorder incompatible study ( discretion investigator ) 5.2.7 Patients prior concurrent malignancy except adequately treat situ carcinoma cervix adequately treat basal cell carcinoma skin 5.2.8 Patients biologic treatment malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>5-FU</keyword>
</DOC>